EMDB/PDB/SASBDBから引用されている文献のデータベース

キーワード
構造解析手法	All X線回折 NMR 電子顕微鏡小角散乱中性子線回折線維回折粉末回折赤外分光 EPR FRET 理論モデルハイブリッド
著者・登録者
ジャーナル
IF	>30 >20 >10 >5 all

タイトル	Catalytic Domain Plasticity of MKK7 Reveals Structural Mechanisms of Allosteric Activation and Diverse Targeting Opportunities.
ジャーナル・号・ページ	Cell Chem Biol, Vol. 27, Page 1285-1295.e4, Year 2020
掲載日	2020年3月27日 (構造データの登録日)
著者	Schroder, M. / Tan, L. / Wang, J. / Liang, Y. / Gray, N.S. / Knapp, S. / Chaikuad, A.
リンク	Cell Chem Biol / PubMed:32783966
手法	X線回折
解像度	1.7 - 2.4 Å
構造データ	PDB-6yfz: Crystal structure of MKK7 (MAP2K7), apo form 手法: X-RAY DIFFRACTION / 解像度: 1.9 Å PDB-6yg0: Crystal structure of S287D,T291D MKK7 (MAP2K7), apo form 手法: X-RAY DIFFRACTION / 解像度: 2.0 Å PDB-6yg1: Crystal structure of MKK7 (MAP2K7) in an active state, allosterically triggered by the N-terminal helix 手法: X-RAY DIFFRACTION / 解像度: 2.22 Å PDB-6yg2: Crystal structure of MKK7 (MAP2K7) in complex with ibrutnib, with covalent and allosteric binding modes 手法: X-RAY DIFFRACTION / 解像度: 2.0 Å PDB-6yg3: Crystal structure of MKK7 (MAP2K7) covalently bound with CPT1-70-1 手法: X-RAY DIFFRACTION / 解像度: 2.05 Å PDB-6yg4: Crystal structure of MKK7 (MAP2K7) in complex with K00007 手法: X-RAY DIFFRACTION / 解像度: 2.3 Å PDB-6yg5: Crystal structure of MKK7 (MAP2K7) in complex with ASC69 手法: X-RAY DIFFRACTION / 解像度: 2.4 Å PDB-6yg6: Crystal structure of MKK7 (MAP2K7) covalently bound with type-II inhibitor TL10-105 手法: X-RAY DIFFRACTION / 解像度: 2.15 Å PDB-6yg7: Crystal structure of MKK7 (MAP2K7) covalently bound with type-II inhibitor SB1-G-23 手法: X-RAY DIFFRACTION / 解像度: 2.2 Å PDB-6yz4: Crystal structure of MKK7 (MAP2K7) with ibrutinib bound at allosteric site 手法: X-RAY DIFFRACTION / 解像度: 1.7 Å
化合物	ChemComp-HOH: WATER ChemComp-NA: Unknown entry / ナトリウムカチオン ChemComp-EDO: 1,2-ETHANEDIOL / エチレングリコ-ル ChemComp-DMS: DIMETHYL SULFOXIDE / 2-チアプロパン2-オキシド / DMSO, 沈殿剤YM ChemComp-1E8: 1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one / イブルチニブ ChemComp-8E8: 1-[(3~{R})-3-[4-azanyl-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]propan-1-one ChemComp-6HF: N-(4-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide ChemComp-SU9: (3Z)-3-(1H-IMIDAZOL-5-YLMETHYLENE)-5-METHOXY-1H-INDOL-2(3H)-ONE / SU-9516 ChemComp-IHH: [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile ChemComp-OQ8: ~{N}-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[2-[[(3~{S})-1-propanoylpyrrolidin-3-yl]amino]pyrimidin-4-yl]oxy-benzamide ChemComp-OQ2*: ~{N}-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-4-methyl-3-[2-[[(3~{R})-1-propanoylpyrrolidin-3-yl]amino]pyrimidin-4-yl]oxy-benzamide
由来	homo sapiens (ヒト)
キーワード	TRANSFERASE / kinase / kinase inhibitor / MKK7 / MEK7 / MAP2K7 / MAP2K / MEK / JNK signaling / Structural Genomics / Structural Genomics Consortium / SGC / Scottish Structural Proteomics Facility / SSPF / allosteric